Cancer - New-wiki

Novel	Symbols	Name 1	Name 2	Pathways 1 Hide	Pathways 2 Hide	Drugs 1 Hide	Drugs 2 Hide	Diseases 1 Hide	Diseases 2 Hide
Novel Novel	Symbols CCNB1 and OTUD7B	Name 1 cyclin B1	Name2 OTU deubiquitinase 7B	Pathway 1 E2F-enabled inhibition of pre-replication complex formation Polo-like kinase mediated events Golgi Cisternae Pericentriolar Stack Reorganization APC/C:Cdc20 mediated degradation of Cyclin B Regulation of APC/C activators between G1/S and early anaphase Phosphorylation of the APC/C Phosphorylation of Emi1 Condensation of Prophase Chromosomes MASTL Facilitates Mitotic Progression Resolution of Sister Chromatid Cohesion Condensation of Prometaphase Chromosomes Regulation of PLK1 Activity at G2/M Transition Activation of NIMA Kinases NEK9, NEK6, NEK7 Initiation of Nuclear Envelope (NE) Reformation Nuclear Pore Complex (NPC) Disassembly Depolymerization of the Nuclear Lamina TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest Mitotic Prophase Cyclin A/B1/B2 associated events during G2/M transition G2/M DNA replication checkpoint Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex The role of GTSE1 in G2/M progression after G2 checkpoint Transcriptional regulation by RUNX2 Nuclear events stimulated by ALK signaling in cancer Regulation of MITF-M-dependent genes involved in cell cycle and proliferation	Pathway 2 TNFR1-induced proapoptotic signaling Regulation of TNFR1 signaling TNFR1-induced NF-kappa-B signaling pathway Ovarian tumor domain proteases	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols CAMLG and VWC2	Name 1 calcium modulating ligand	Name2 von Willebrand factor C domain containing 2	Pathway 1 Insertion of tail-anchored proteins into the endoplasmic reticulum membrane	Pathway 2	Drugs 1 Cyclosporine Voclosporin	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols CAMLG and PKHD1	Name 1 calcium modulating ligand	Name2 PKHD1 ciliary IPT domain containing fibrocystin/polyductin	Pathway 1 Insertion of tail-anchored proteins into the endoplasmic reticulum membrane	Pathway 2	Drugs 1 Cyclosporine Voclosporin	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols CSK and INSR	Name 1 C-terminal Src kinase	Name2 insulin receptor	Pathway 1 GAB1 signalosome Phosphorylation of CD3 and TCR zeta chains Integrin signaling Co-inhibition by PD-1 MAP2K and MAPK activation Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF RHOH GTPase cycle Signaling downstream of RAS mutants Signaling by RAF1 mutants Negative regulation of FLT3	Pathway 2 PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling IRS activation Signal attenuation Insulin receptor signalling cascade Signaling by Insulin receptor Insulin receptor recycling	Drugs 1 Dasatinib Staurosporine TG-100801 Fostamatinib	Drugs 2 Insulin human Insulin lispro Insulin glargine Insulin pork Mecasermin Insulin aspart Insulin detemir Insulin glulisine Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate NN344 AT1391 Linsitinib [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID Chromic chloride Insulin beef Insulin degludec Insulin argine Insulin peglispro Insulin tregopil Fostamatinib Brigatinib Mecasermin rinfabate BMS-754807 KW-2450 free base	Diseases 1	Diseases 2 Leprechaunism ; Donohue syndrome Rabson-Mendenhall syndrome
Novel Novel	Symbols CSK and DOK2	Name 1 C-terminal Src kinase	Name2 docking protein 2	Pathway 1 GAB1 signalosome Phosphorylation of CD3 and TCR zeta chains Integrin signaling Co-inhibition by PD-1 MAP2K and MAPK activation Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF RHOH GTPase cycle Signaling downstream of RAS mutants Signaling by RAF1 mutants Negative regulation of FLT3	Pathway 2 Tie2 Signaling RET signaling	Drugs 1 Dasatinib Staurosporine TG-100801 Fostamatinib	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols DCN and TNF	Name 1 decorin	Name2 tumor necrosis factor	Pathway 1 Degradation of the extracellular matrix Glycosaminoglycan-protein linkage region biosynthesis CS-GAG biosynthesis DS-GAG biosynthesis CS/DS degradation ECM proteoglycans ECM proteoglycans Defective B4GALT7 causes EDS, progeroid type Defective B3GAT3 causes JDSSDHD Defective CHST3 causes SEDCJD Defective CHST14 causes EDS, musculocontractural type Defective CHSY1 causes TPBS Defective B3GALT6 causes EDSP2 and SEMDJL1	Pathway 2 Transcriptional regulation of white adipocyte differentiation TNFR1-induced proapoptotic signaling Regulation of TNFR1 signaling TNFR1-induced NF-kappa-B signaling pathway TNFR1-mediated ceramide production TNFR2 non-canonical NF-kB pathway Interleukin-10 signaling Interleukin-4 and Interleukin-13 signaling TNF signaling Differentiation of naive CD+ T cells to T helper 1 cells (Th1 cells)	Drugs 1	Drugs 2 Etanercept Adalimumab Infliximab Chloroquine Epinephrine Pseudoephedrine Clenbuterol Pranlukast Amrinone Trichostatin A Afelimomab YSIL6 SD118 PN0621 OMS-103HP Talmapimod VX-702 Atiprimod CRx-139 CYT007-TNFQb Andrographolide Ethyl pyruvate AME-527 PR-104 Plinabulin Dexanabinol Onercept Golimumab Certolizumab pegol Pomalidomide Polaprezinc Foreskin fibroblast (neonatal) Foreskin keratinocyte (neonatal) Bryostatin 1 Binimetinib Dilmapimod Glycyrrhizic acid	Diseases 1 Congenital stromal corneal dystrophy (CSCD); Congenital hereditary stromal dystrophy; Witschel dystrophy	Diseases 2 Graft-versus-host disease Systemic lupus erythematosus Allograft rejection Asthma
Novel Novel	Symbols DCN and FBN1	Name 1 decorin	Name2 fibrillin 1	Pathway 1 Degradation of the extracellular matrix Glycosaminoglycan-protein linkage region biosynthesis CS-GAG biosynthesis DS-GAG biosynthesis CS/DS degradation ECM proteoglycans ECM proteoglycans Defective B4GALT7 causes EDS, progeroid type Defective B3GAT3 causes JDSSDHD Defective CHST3 causes SEDCJD Defective CHST14 causes EDS, musculocontractural type Defective CHSY1 causes TPBS Defective B3GALT6 causes EDSP2 and SEMDJL1	Pathway 2 Degradation of the extracellular matrix Degradation of the extracellular matrix Elastic fibre formation Molecules associated with elastic fibres Molecules associated with elastic fibres Integrin cell surface interactions TGF-beta receptor signaling activates SMADs Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) Post-translational protein phosphorylation	Drugs 1	Drugs 2	Diseases 1 Congenital stromal corneal dystrophy (CSCD); Congenital hereditary stromal dystrophy; Witschel dystrophy	Diseases 2 Geleophysic dysplasia Weill-Marchesani syndrome, including: Weill-Marchesani syndrome; Weill-Marchesani-like syndrome Shprintzen-Goldberg syndrome Ectopia lentis MASS phenotype Marfan syndrome, including: Marfan syndrome (MFS); Neonatal MFS; Atypically severe MFS; New variant of MFS
Novel Novel	Symbols DCN and MMP7	Name 1 decorin	Name2 matrix metallopeptidase 7	Pathway 1 Degradation of the extracellular matrix Glycosaminoglycan-protein linkage region biosynthesis CS-GAG biosynthesis DS-GAG biosynthesis CS/DS degradation ECM proteoglycans ECM proteoglycans Defective B4GALT7 causes EDS, progeroid type Defective B3GAT3 causes JDSSDHD Defective CHST3 causes SEDCJD Defective CHST14 causes EDS, musculocontractural type Defective CHSY1 causes TPBS Defective B3GALT6 causes EDSP2 and SEMDJL1	Pathway 2 Collagen degradation Degradation of the extracellular matrix Degradation of the extracellular matrix Activation of Matrix Metalloproteinases Assembly of collagen fibrils and other multimeric structures Extra-nuclear estrogen signaling	Drugs 1	Drugs 2 Marimastat (1R)-N,6-DIHYDROXY-7-METHOXY-2-[(4-METHOXYPHENYL)SULFONYL]-1,2,3,4-TETRAHYDROISOQUINOLINE-1-CARBOXAMIDE N4-HYDROXY-2-ISOBUTYL-N1-(9-OXO-1,8-DIAZA-TRICYCLO[10.6.1.013,18]NONADECA-12(19),13,15,17-TETRAEN-10-YL)-SUCCINAMIDE 5-METHYL-3-(9-OXO-1,8-DIAZA-TRICYCLO[10.6.1.013,18]NONADECA-12(19),13,15,17-TETRAEN-10-YLCARBAMOYL)-HEXANOIC ACID	Diseases 1 Congenital stromal corneal dystrophy (CSCD); Congenital hereditary stromal dystrophy; Witschel dystrophy	Diseases 2
Novel Novel	Symbols ARNT and AHRR	Name 1 aryl hydrocarbon receptor nuclear translocator	Name2 aryl hydrocarbon receptor repressor	Pathway 1 Regulation of gene expression by Hypoxia-inducible Factor PPARA activates gene expression Phase I - Functionalization of compounds Endogenous sterols Xenobiotics Aryl hydrocarbon receptor signalling NPAS4 regulates expression of target genes NPAS4 regulates expression of target genes	Pathway 2 PPARA activates gene expression Phase I - Functionalization of compounds Endogenous sterols Xenobiotics Aryl hydrocarbon receptor signalling	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols ARNT and NCOA7	Name 1 aryl hydrocarbon receptor nuclear translocator	Name2 nuclear receptor coactivator 7	Pathway 1 Regulation of gene expression by Hypoxia-inducible Factor PPARA activates gene expression Phase I - Functionalization of compounds Endogenous sterols Xenobiotics Aryl hydrocarbon receptor signalling NPAS4 regulates expression of target genes NPAS4 regulates expression of target genes	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols ARNT and HEY2	Name 1 aryl hydrocarbon receptor nuclear translocator	Name2 hes related family bHLH transcription factor with YRPW motif 2	Pathway 1 Regulation of gene expression by Hypoxia-inducible Factor PPARA activates gene expression Phase I - Functionalization of compounds Endogenous sterols Xenobiotics Aryl hydrocarbon receptor signalling NPAS4 regulates expression of target genes NPAS4 regulates expression of target genes	Pathway 2 NOTCH1 Intracellular Domain Regulates Transcription Constitutive Signaling by NOTCH1 PEST Domain Mutants Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants RUNX2 regulates osteoblast differentiation NOTCH3 Intracellular Domain Regulates Transcription NOTCH4 Intracellular Domain Regulates Transcription Cardiogenesis	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols ARNT and HEY1	Name 1 aryl hydrocarbon receptor nuclear translocator	Name2 hes related family bHLH transcription factor with YRPW motif 1	Pathway 1 Regulation of gene expression by Hypoxia-inducible Factor PPARA activates gene expression Phase I - Functionalization of compounds Endogenous sterols Xenobiotics Aryl hydrocarbon receptor signalling NPAS4 regulates expression of target genes NPAS4 regulates expression of target genes	Pathway 2 NOTCH1 Intracellular Domain Regulates Transcription Constitutive Signaling by NOTCH1 PEST Domain Mutants Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants RUNX2 regulates osteoblast differentiation NOTCH3 Intracellular Domain Regulates Transcription NOTCH4 Intracellular Domain Regulates Transcription Cardiogenesis	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols ARNT and CASP9	Name 1 aryl hydrocarbon receptor nuclear translocator	Name2 caspase 9	Pathway 1 Regulation of gene expression by Hypoxia-inducible Factor PPARA activates gene expression Phase I - Functionalization of compounds Endogenous sterols Xenobiotics Aryl hydrocarbon receptor signalling NPAS4 regulates expression of target genes NPAS4 regulates expression of target genes	Pathway 2 Formation of apoptosome Activation of caspases through apoptosome-mediated cleavage SMAC (DIABLO) binds to IAPs SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes NOD1/2 Signaling Pathway AKT phosphorylates targets in the cytosol Caspase activation via Dependence Receptors in the absence of ligand Constitutive Signaling by AKT1 E17K in Cancer Regulation of the apoptosome activity Regulation of the apoptosome activity	Drugs 1	Drugs 2 Pamidronic acid	Diseases 1	Diseases 2
Novel Novel	Symbols ARNT and TACC3	Name 1 aryl hydrocarbon receptor nuclear translocator	Name2 transforming acidic coiled-coil containing protein 3	Pathway 1 Regulation of gene expression by Hypoxia-inducible Factor PPARA activates gene expression Phase I - Functionalization of compounds Endogenous sterols Xenobiotics Aryl hydrocarbon receptor signalling NPAS4 regulates expression of target genes NPAS4 regulates expression of target genes	Pathway 2 NOTCH3 Activation and Transmission of Signal to the Nucleus Negative regulation of NOTCH4 signaling	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols ARNT and FGFR4	Name 1 aryl hydrocarbon receptor nuclear translocator	Name2 fibroblast growth factor receptor 4	Pathway 1 Regulation of gene expression by Hypoxia-inducible Factor PPARA activates gene expression Phase I - Functionalization of compounds Endogenous sterols Xenobiotics Aryl hydrocarbon receptor signalling NPAS4 regulates expression of target genes NPAS4 regulates expression of target genes	Pathway 2 PI3K Cascade PIP3 activates AKT signaling betaKlotho-mediated ligand binding FGFR4 mutant receptor activation FGFR4 ligand binding and activation Constitutive Signaling by Aberrant PI3K in Cancer Phospholipase C-mediated cascade; FGFR4 FRS-mediated FGFR4 signaling SHC-mediated cascade:FGFR4 PI-3K cascade:FGFR4 Negative regulation of FGFR4 signaling Signaling by FGFR4 in disease RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	Drugs 1	Drugs 2 Heparin Ponatinib Lenvatinib Infigratinib Erdafitinib Pemigatinib Futibatinib	Diseases 1	Diseases 2
Novel Novel	Symbols ARNT and CD44	Name 1 aryl hydrocarbon receptor nuclear translocator	Name2 CD44 molecule (IN blood group)	Pathway 1 Regulation of gene expression by Hypoxia-inducible Factor PPARA activates gene expression Phase I - Functionalization of compounds Endogenous sterols Xenobiotics Aryl hydrocarbon receptor signalling NPAS4 regulates expression of target genes NPAS4 regulates expression of target genes	Pathway 2 Degradation of the extracellular matrix Cell surface interactions at the vascular wall Hyaluronan metabolism Integrin cell surface interactions Hyaluronan degradation Neutrophil degranulation Interferon gamma signaling Developmental Lineage of Mammary Gland Luminal Epithelial Cells Developmental Lineage of Mammary Gland Myoepithelial Cells Developmental Lineage of Mammary Stem Cells	Drugs 1	Drugs 2 Bivatuzumab Hyaluronic acid	Diseases 1	Diseases 2 Gastric cancer
Novel Novel	Symbols ARNT and PDGFRA	Name 1 aryl hydrocarbon receptor nuclear translocator	Name2 platelet derived growth factor receptor alpha	Pathway 1 Regulation of gene expression by Hypoxia-inducible Factor PPARA activates gene expression Phase I - Functionalization of compounds Endogenous sterols Xenobiotics Aryl hydrocarbon receptor signalling NPAS4 regulates expression of target genes NPAS4 regulates expression of target genes	Pathway 2 PIP3 activates AKT signaling Downstream signal transduction Signaling by PDGF Constitutive Signaling by Aberrant PI3K in Cancer RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants Signaling by PDGFRA extracellular domain mutants Imatinib-resistant PDGFR mutants Sunitinib-resistant PDGFR mutants Regorafenib-resistant PDGFR mutants Sorafenib-resistant PDGFR mutants PDGFR mutants bind TKIs	Drugs 1	Drugs 2 Becaplermin Imatinib Sunitinib XL820 Olaratumab Pazopanib Midostaurin Regorafenib Ponatinib Lenvatinib Nintedanib Foreskin keratinocyte (neonatal) Tivozanib Fostamatinib Erdafitinib Amuvatinib Ripretinib	Diseases 1	Diseases 2 Glioma
Novel Novel	Symbols GADD45A and IGSF21	Name 1 growth arrest and DNA damage inducible alpha	Name2 immunoglobin superfamily member 21	Pathway 1 TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest FOXO-mediated transcription of cell cycle genes	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols DRD3 and CLIC6	Name 1 dopamine receptor D3	Name2 chloride intracellular channel 6	Pathway 1 Dopamine receptors G alpha (i) signalling events	Pathway 2	Drugs 1 Ziprasidone Cabergoline Ropinirole Dihydroergotamine Olanzapine Clozapine Sulpiride Loxapine Remoxipride Pramipexole Chlorpromazine Buspirone Haloperidol Amoxapine Lisuride Apomorphine Flupentixol Dopamine Ergoloid mesylate Pimozide Domperidone Pergolide Bromocriptine Quetiapine Levodopa Aripiprazole Chlorprothixene Paliperidone Yohimbine Methotrimeprazine Iloperidone Rotigotine Norclozapine Cariprazine Mianserin Asenapine Amisulpride Sarizotan Sumanirole Nandrolone decanoate Captodiame AS-8112 Blonanserin Pipamperone Tianeptine Dihydro-alpha-ergocryptine Epicriptine Pardoprunox Piribedil Tiapride Dihydroergocristine Aripiprazole lauroxil	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols SNRPE and FOXP1	Name 1 small nuclear ribonucleoprotein polypeptide E	Name2 forkhead box P1	Pathway 1 SLBP independent Processing of Histone Pre-mRNAs snRNP Assembly mRNA Splicing - Major Pathway mRNA Splicing - Minor Pathway RNA Polymerase II Transcription Termination SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs SARS-CoV-2 modulates host translation machinery	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols CCNB1 and OTUD7B	Name 1 cyclin B1	Name2 OTU deubiquitinase 7B	Pathway 1 E2F-enabled inhibition of pre-replication complex formation Polo-like kinase mediated events Golgi Cisternae Pericentriolar Stack Reorganization APC/C:Cdc20 mediated degradation of Cyclin B Regulation of APC/C activators between G1/S and early anaphase Phosphorylation of the APC/C Phosphorylation of Emi1 Condensation of Prophase Chromosomes MASTL Facilitates Mitotic Progression Resolution of Sister Chromatid Cohesion Condensation of Prometaphase Chromosomes Regulation of PLK1 Activity at G2/M Transition Activation of NIMA Kinases NEK9, NEK6, NEK7 Initiation of Nuclear Envelope (NE) Reformation Nuclear Pore Complex (NPC) Disassembly Depolymerization of the Nuclear Lamina TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest Mitotic Prophase Cyclin A/B1/B2 associated events during G2/M transition G2/M DNA replication checkpoint Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex The role of GTSE1 in G2/M progression after G2 checkpoint Transcriptional regulation by RUNX2 Nuclear events stimulated by ALK signaling in cancer Regulation of MITF-M-dependent genes involved in cell cycle and proliferation	Pathway 2 TNFR1-induced proapoptotic signaling Regulation of TNFR1 signaling TNFR1-induced NF-kappa-B signaling pathway Ovarian tumor domain proteases	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols CAMLG and VWC2	Name 1 calcium modulating ligand	Name2 von Willebrand factor C domain containing 2	Pathway 1 Insertion of tail-anchored proteins into the endoplasmic reticulum membrane	Pathway 2	Drugs 1 Cyclosporine Voclosporin	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols CAMLG and PKHD1	Name 1 calcium modulating ligand	Name2 PKHD1 ciliary IPT domain containing fibrocystin/polyductin	Pathway 1 Insertion of tail-anchored proteins into the endoplasmic reticulum membrane	Pathway 2	Drugs 1 Cyclosporine Voclosporin	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols CSK and INSR	Name 1 C-terminal Src kinase	Name2 insulin receptor	Pathway 1 GAB1 signalosome Phosphorylation of CD3 and TCR zeta chains Integrin signaling Co-inhibition by PD-1 MAP2K and MAPK activation Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF RHOH GTPase cycle Signaling downstream of RAS mutants Signaling by RAF1 mutants Negative regulation of FLT3	Pathway 2 PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling IRS activation Signal attenuation Insulin receptor signalling cascade Signaling by Insulin receptor Insulin receptor recycling	Drugs 1 Dasatinib Staurosporine TG-100801 Fostamatinib	Drugs 2 Insulin human Insulin lispro Insulin glargine Insulin pork Mecasermin Insulin aspart Insulin detemir Insulin glulisine Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate NN344 AT1391 Linsitinib [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID Chromic chloride Insulin beef Insulin degludec Insulin argine Insulin peglispro Insulin tregopil Fostamatinib Brigatinib Mecasermin rinfabate BMS-754807 KW-2450 free base	Diseases 1	Diseases 2 Leprechaunism ; Donohue syndrome Rabson-Mendenhall syndrome
Novel	Symbols CSK and DOK2	Name 1 C-terminal Src kinase	Name2 docking protein 2	Pathway 1 GAB1 signalosome Phosphorylation of CD3 and TCR zeta chains Integrin signaling Co-inhibition by PD-1 MAP2K and MAPK activation Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF RHOH GTPase cycle Signaling downstream of RAS mutants Signaling by RAF1 mutants Negative regulation of FLT3	Pathway 2 Tie2 Signaling RET signaling	Drugs 1 Dasatinib Staurosporine TG-100801 Fostamatinib	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols DCN and TNF	Name 1 decorin	Name2 tumor necrosis factor	Pathway 1 Degradation of the extracellular matrix Glycosaminoglycan-protein linkage region biosynthesis CS-GAG biosynthesis DS-GAG biosynthesis CS/DS degradation ECM proteoglycans ECM proteoglycans Defective B4GALT7 causes EDS, progeroid type Defective B3GAT3 causes JDSSDHD Defective CHST3 causes SEDCJD Defective CHST14 causes EDS, musculocontractural type Defective CHSY1 causes TPBS Defective B3GALT6 causes EDSP2 and SEMDJL1	Pathway 2 Transcriptional regulation of white adipocyte differentiation TNFR1-induced proapoptotic signaling Regulation of TNFR1 signaling TNFR1-induced NF-kappa-B signaling pathway TNFR1-mediated ceramide production TNFR2 non-canonical NF-kB pathway Interleukin-10 signaling Interleukin-4 and Interleukin-13 signaling TNF signaling Differentiation of naive CD+ T cells to T helper 1 cells (Th1 cells)	Drugs 1	Drugs 2 Etanercept Adalimumab Infliximab Chloroquine Epinephrine Pseudoephedrine Clenbuterol Pranlukast Amrinone Trichostatin A Afelimomab YSIL6 SD118 PN0621 OMS-103HP Talmapimod VX-702 Atiprimod CRx-139 CYT007-TNFQb Andrographolide Ethyl pyruvate AME-527 PR-104 Plinabulin Dexanabinol Onercept Golimumab Certolizumab pegol Pomalidomide Polaprezinc Foreskin fibroblast (neonatal) Foreskin keratinocyte (neonatal) Bryostatin 1 Binimetinib Dilmapimod Glycyrrhizic acid	Diseases 1 Congenital stromal corneal dystrophy (CSCD); Congenital hereditary stromal dystrophy; Witschel dystrophy	Diseases 2 Graft-versus-host disease Systemic lupus erythematosus Allograft rejection Asthma
Novel	Symbols DCN and FBN1	Name 1 decorin	Name2 fibrillin 1	Pathway 1 Degradation of the extracellular matrix Glycosaminoglycan-protein linkage region biosynthesis CS-GAG biosynthesis DS-GAG biosynthesis CS/DS degradation ECM proteoglycans ECM proteoglycans Defective B4GALT7 causes EDS, progeroid type Defective B3GAT3 causes JDSSDHD Defective CHST3 causes SEDCJD Defective CHST14 causes EDS, musculocontractural type Defective CHSY1 causes TPBS Defective B3GALT6 causes EDSP2 and SEMDJL1	Pathway 2 Degradation of the extracellular matrix Degradation of the extracellular matrix Elastic fibre formation Molecules associated with elastic fibres Molecules associated with elastic fibres Integrin cell surface interactions TGF-beta receptor signaling activates SMADs Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) Post-translational protein phosphorylation	Drugs 1	Drugs 2	Diseases 1 Congenital stromal corneal dystrophy (CSCD); Congenital hereditary stromal dystrophy; Witschel dystrophy	Diseases 2 Geleophysic dysplasia Weill-Marchesani syndrome, including: Weill-Marchesani syndrome; Weill-Marchesani-like syndrome Shprintzen-Goldberg syndrome Ectopia lentis MASS phenotype Marfan syndrome, including: Marfan syndrome (MFS); Neonatal MFS; Atypically severe MFS; New variant of MFS
Novel	Symbols DCN and MMP7	Name 1 decorin	Name2 matrix metallopeptidase 7	Pathway 1 Degradation of the extracellular matrix Glycosaminoglycan-protein linkage region biosynthesis CS-GAG biosynthesis DS-GAG biosynthesis CS/DS degradation ECM proteoglycans ECM proteoglycans Defective B4GALT7 causes EDS, progeroid type Defective B3GAT3 causes JDSSDHD Defective CHST3 causes SEDCJD Defective CHST14 causes EDS, musculocontractural type Defective CHSY1 causes TPBS Defective B3GALT6 causes EDSP2 and SEMDJL1	Pathway 2 Collagen degradation Degradation of the extracellular matrix Degradation of the extracellular matrix Activation of Matrix Metalloproteinases Assembly of collagen fibrils and other multimeric structures Extra-nuclear estrogen signaling	Drugs 1	Drugs 2 Marimastat (1R)-N,6-DIHYDROXY-7-METHOXY-2-[(4-METHOXYPHENYL)SULFONYL]-1,2,3,4-TETRAHYDROISOQUINOLINE-1-CARBOXAMIDE N4-HYDROXY-2-ISOBUTYL-N1-(9-OXO-1,8-DIAZA-TRICYCLO[10.6.1.013,18]NONADECA-12(19),13,15,17-TETRAEN-10-YL)-SUCCINAMIDE 5-METHYL-3-(9-OXO-1,8-DIAZA-TRICYCLO[10.6.1.013,18]NONADECA-12(19),13,15,17-TETRAEN-10-YLCARBAMOYL)-HEXANOIC ACID	Diseases 1 Congenital stromal corneal dystrophy (CSCD); Congenital hereditary stromal dystrophy; Witschel dystrophy	Diseases 2
Novel	Symbols ARNT and AHRR	Name 1 aryl hydrocarbon receptor nuclear translocator	Name2 aryl hydrocarbon receptor repressor	Pathway 1 Regulation of gene expression by Hypoxia-inducible Factor PPARA activates gene expression Phase I - Functionalization of compounds Endogenous sterols Xenobiotics Aryl hydrocarbon receptor signalling NPAS4 regulates expression of target genes NPAS4 regulates expression of target genes	Pathway 2 PPARA activates gene expression Phase I - Functionalization of compounds Endogenous sterols Xenobiotics Aryl hydrocarbon receptor signalling	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols ARNT and NCOA7	Name 1 aryl hydrocarbon receptor nuclear translocator	Name2 nuclear receptor coactivator 7	Pathway 1 Regulation of gene expression by Hypoxia-inducible Factor PPARA activates gene expression Phase I - Functionalization of compounds Endogenous sterols Xenobiotics Aryl hydrocarbon receptor signalling NPAS4 regulates expression of target genes NPAS4 regulates expression of target genes	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols ARNT and HEY2	Name 1 aryl hydrocarbon receptor nuclear translocator	Name2 hes related family bHLH transcription factor with YRPW motif 2	Pathway 1 Regulation of gene expression by Hypoxia-inducible Factor PPARA activates gene expression Phase I - Functionalization of compounds Endogenous sterols Xenobiotics Aryl hydrocarbon receptor signalling NPAS4 regulates expression of target genes NPAS4 regulates expression of target genes	Pathway 2 NOTCH1 Intracellular Domain Regulates Transcription Constitutive Signaling by NOTCH1 PEST Domain Mutants Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants RUNX2 regulates osteoblast differentiation NOTCH3 Intracellular Domain Regulates Transcription NOTCH4 Intracellular Domain Regulates Transcription Cardiogenesis	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols ARNT and HEY1	Name 1 aryl hydrocarbon receptor nuclear translocator	Name2 hes related family bHLH transcription factor with YRPW motif 1	Pathway 1 Regulation of gene expression by Hypoxia-inducible Factor PPARA activates gene expression Phase I - Functionalization of compounds Endogenous sterols Xenobiotics Aryl hydrocarbon receptor signalling NPAS4 regulates expression of target genes NPAS4 regulates expression of target genes	Pathway 2 NOTCH1 Intracellular Domain Regulates Transcription Constitutive Signaling by NOTCH1 PEST Domain Mutants Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants RUNX2 regulates osteoblast differentiation NOTCH3 Intracellular Domain Regulates Transcription NOTCH4 Intracellular Domain Regulates Transcription Cardiogenesis	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols ARNT and CASP9	Name 1 aryl hydrocarbon receptor nuclear translocator	Name2 caspase 9	Pathway 1 Regulation of gene expression by Hypoxia-inducible Factor PPARA activates gene expression Phase I - Functionalization of compounds Endogenous sterols Xenobiotics Aryl hydrocarbon receptor signalling NPAS4 regulates expression of target genes NPAS4 regulates expression of target genes	Pathway 2 Formation of apoptosome Activation of caspases through apoptosome-mediated cleavage SMAC (DIABLO) binds to IAPs SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes NOD1/2 Signaling Pathway AKT phosphorylates targets in the cytosol Caspase activation via Dependence Receptors in the absence of ligand Constitutive Signaling by AKT1 E17K in Cancer Regulation of the apoptosome activity Regulation of the apoptosome activity	Drugs 1	Drugs 2 Pamidronic acid	Diseases 1	Diseases 2
Novel	Symbols ARNT and TACC3	Name 1 aryl hydrocarbon receptor nuclear translocator	Name2 transforming acidic coiled-coil containing protein 3	Pathway 1 Regulation of gene expression by Hypoxia-inducible Factor PPARA activates gene expression Phase I - Functionalization of compounds Endogenous sterols Xenobiotics Aryl hydrocarbon receptor signalling NPAS4 regulates expression of target genes NPAS4 regulates expression of target genes	Pathway 2 NOTCH3 Activation and Transmission of Signal to the Nucleus Negative regulation of NOTCH4 signaling	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols ARNT and FGFR4	Name 1 aryl hydrocarbon receptor nuclear translocator	Name2 fibroblast growth factor receptor 4	Pathway 1 Regulation of gene expression by Hypoxia-inducible Factor PPARA activates gene expression Phase I - Functionalization of compounds Endogenous sterols Xenobiotics Aryl hydrocarbon receptor signalling NPAS4 regulates expression of target genes NPAS4 regulates expression of target genes	Pathway 2 PI3K Cascade PIP3 activates AKT signaling betaKlotho-mediated ligand binding FGFR4 mutant receptor activation FGFR4 ligand binding and activation Constitutive Signaling by Aberrant PI3K in Cancer Phospholipase C-mediated cascade; FGFR4 FRS-mediated FGFR4 signaling SHC-mediated cascade:FGFR4 PI-3K cascade:FGFR4 Negative regulation of FGFR4 signaling Signaling by FGFR4 in disease RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	Drugs 1	Drugs 2 Heparin Ponatinib Lenvatinib Infigratinib Erdafitinib Pemigatinib Futibatinib	Diseases 1	Diseases 2
Novel	Symbols ARNT and CD44	Name 1 aryl hydrocarbon receptor nuclear translocator	Name2 CD44 molecule (IN blood group)	Pathway 1 Regulation of gene expression by Hypoxia-inducible Factor PPARA activates gene expression Phase I - Functionalization of compounds Endogenous sterols Xenobiotics Aryl hydrocarbon receptor signalling NPAS4 regulates expression of target genes NPAS4 regulates expression of target genes	Pathway 2 Degradation of the extracellular matrix Cell surface interactions at the vascular wall Hyaluronan metabolism Integrin cell surface interactions Hyaluronan degradation Neutrophil degranulation Interferon gamma signaling Developmental Lineage of Mammary Gland Luminal Epithelial Cells Developmental Lineage of Mammary Gland Myoepithelial Cells Developmental Lineage of Mammary Stem Cells	Drugs 1	Drugs 2 Bivatuzumab Hyaluronic acid	Diseases 1	Diseases 2 Gastric cancer
Novel	Symbols ARNT and PDGFRA	Name 1 aryl hydrocarbon receptor nuclear translocator	Name2 platelet derived growth factor receptor alpha	Pathway 1 Regulation of gene expression by Hypoxia-inducible Factor PPARA activates gene expression Phase I - Functionalization of compounds Endogenous sterols Xenobiotics Aryl hydrocarbon receptor signalling NPAS4 regulates expression of target genes NPAS4 regulates expression of target genes	Pathway 2 PIP3 activates AKT signaling Downstream signal transduction Signaling by PDGF Constitutive Signaling by Aberrant PI3K in Cancer RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants Signaling by PDGFRA extracellular domain mutants Imatinib-resistant PDGFR mutants Sunitinib-resistant PDGFR mutants Regorafenib-resistant PDGFR mutants Sorafenib-resistant PDGFR mutants PDGFR mutants bind TKIs	Drugs 1	Drugs 2 Becaplermin Imatinib Sunitinib XL820 Olaratumab Pazopanib Midostaurin Regorafenib Ponatinib Lenvatinib Nintedanib Foreskin keratinocyte (neonatal) Tivozanib Fostamatinib Erdafitinib Amuvatinib Ripretinib	Diseases 1	Diseases 2 Glioma
Novel	Symbols GADD45A and IGSF21	Name 1 growth arrest and DNA damage inducible alpha	Name2 immunoglobin superfamily member 21	Pathway 1 TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest FOXO-mediated transcription of cell cycle genes	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols DRD3 and CLIC6	Name 1 dopamine receptor D3	Name2 chloride intracellular channel 6	Pathway 1 Dopamine receptors G alpha (i) signalling events	Pathway 2	Drugs 1 Ziprasidone Cabergoline Ropinirole Dihydroergotamine Olanzapine Clozapine Sulpiride Loxapine Remoxipride Pramipexole Chlorpromazine Buspirone Haloperidol Amoxapine Lisuride Apomorphine Flupentixol Dopamine Ergoloid mesylate Pimozide Domperidone Pergolide Bromocriptine Quetiapine Levodopa Aripiprazole Chlorprothixene Paliperidone Yohimbine Methotrimeprazine Iloperidone Rotigotine Norclozapine Cariprazine Mianserin Asenapine Amisulpride Sarizotan Sumanirole Nandrolone decanoate Captodiame AS-8112 Blonanserin Pipamperone Tianeptine Dihydro-alpha-ergocryptine Epicriptine Pardoprunox Piribedil Tiapride Dihydroergocristine Aripiprazole lauroxil	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols SNRPE and FOXP1	Name 1 small nuclear ribonucleoprotein polypeptide E	Name2 forkhead box P1	Pathway 1 SLBP independent Processing of Histone Pre-mRNAs snRNP Assembly mRNA Splicing - Major Pathway mRNA Splicing - Minor Pathway RNA Polymerase II Transcription Termination SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs SARS-CoV-2 modulates host translation machinery	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2

Page 31 out of 98 pages

Search Results : Cancer